SEARCH   
 
Media Center
Longcom announces reissuance of GMP certificate for Vaccae®
26.07.2016 Hits: Large In Small

 

CHONGQING, July 21th 2011, Thursday —Chongqing Zhifei Biological Products Co., Ltd. (Zhifei, SZSE: 300122), a leading provider of biopharmaceutical products in China, announced that the China Food and Drug Administration (“CFDA”) has reissued the Good Manufacturing Practices (“GMP”) certificate (valid until Dec. 31th, 2013) to Anhui Longcom Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhifei, for its TB product---Mycobacterium Vaccae for Injection (“Vaccae®”).
 
Longcom has been comprehensively implementing GMP surveillance and management in the whole process of manufacturing and quality control. Sticking to the company''''s core value that quality outweighs everything, Longcom will strive harder to be a leading modern biopharmaceutical company in China and the world in the future.
 
About Zhifei

Zhifei, a leading vaccine enterprise in China based on research, development, manufacturing and marketing, is committed to improving children‘s physical quality by sparing no efforts to supply innovative vaccines with high quality and low price for society under the principle of "social benefits first, economic profits second". It has four wholly-owned subsidiaries---Beijing Lvzhu Biopharmaceutical Co., Ltd., Anhui Longcom Biopharmaceutical Co., Ltd., Chongqing Zhiren Biotechnology Co., Ltd. and Zhifei (HONG KONG) Ltd. For further information, please visit http://www.zhifeishengwu.com